AGEN : Summary for Agenus Inc. - Yahoo Finance

U.S. Markets closed

Agenus Inc. (AGEN)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.70+0.10 (+2.78%)
At close: 4:00PM EDT

3.74 0.04 (1.08%)
After hours: 5:26PM EDT

People also watch
CTICARRYCRISEXELARIA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close3.60
Open3.64
Bid2.60 x 200
Ask3.75 x 300
Day's Range3.52 - 3.73
52 Week Range2.97 - 7.49
Volume963,277
Avg. Volume1,237,977
Market Cap363.82M
Beta2.62
PE Ratio (TTM)-2.53
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journalsyesterday

    First malaria vaccine to be tested in Africa, with boost from Lexington's Agenus

    The World Health Organization said Monday that the world’s first malaria vaccine, which features a key component made by Lexington biotech Agenus, will be available in parts of Africa beginning next year. The WHO’s African regional office said that Ghana, Kenya and Malawi would participate in a pilot program for the injectable vaccine, which was developed by U.K. drug giant GlaxoSmithKline (GSK) with funding from the Bill & Melinda Gates Foundation. The vaccine contains a so-called adjuvant made by Agenus (AGEN), which is designed to boost the body’s immune response.

  • What's in Store for Agenus (AGEN) this Earnings Season?
    Zacks2 days ago

    What's in Store for Agenus (AGEN) this Earnings Season?

    Agenus Inc. (AGEN) is expected to report first-quarter 2017 results later this month or early next month.

  • PR Newswire6 days ago

    Phase 1/2 Clinical Trial of Agenus' anti-PD-1 Antibody Begins

    LEXINGTON, Mass., April 20, 2017 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that the first patient has been dosed in a Phase 1/2 clinical trial of its anti-PD-1 antibody, AGEN2034. Part 2 of the trial is planned to evaluate the recommended dose of AGEN2034 in patients with second line cervical cancer. "The entry of our PD-1 antagonist into the clinic is key to our strategy to pursue combination therapies," said Garo H. Armen, Ph.D. Chairman and CEO of Agenus.